In vitro antifungal susceptibility of polyhexamethylene biguanide against common superficial fungal species

Abstract

Abstract:

Objective To determine the in vitro antifungal susceptibility of polyhexamethylene biguanide (PHMB) against common superficial fungal species. Methods We used the standard broth microdilution method and agar dilution method to evaluate the minimal inhibitory concentration (MIC) and minimal fungicidal concentration (MFC) of PHMB against the clinical isolates of Trichophyton rubrum, T. mentagrophytes, Microsporum canis and Candida albicans. Results Broth microdilution method showed that MIC range of PHMB powder against T. rubrum was 1.0~4.0 μg/mL, the MFC range was 2.0~8.0 μg/mL. The MIC range of T. mentagrophytes was 2.0~4.0 μg/mL and the MFC was 4.0 μg/mL. To M. canis the MIC range was 2.0~4.0 μg/mL and MFC range was 2.0~4.0 μg/mL. To C. albicans the MIC range turned out to be 0.3~5.0 μg/mL and the MFC range was 5.0~10.0 μg/mL. The agar dilution method showed there were none T. rubrum, T. mentagrophytes and M.canis colony growth on agar plate when PHMB liquid at the concentration of 1.25%. There was none C. albicans colony growth at the concentration of 0.32%. After added the penetration enhancer of azone, the result showed no difference. Conclusions PHMB showed great in vitro efficacy against T. rubrum, T. mentagrophytes, M. canis and C. albicans, suggesting a potential therapeutic choice for treatment of superficial fungal infection.

Key words: polyhexamethylene biguanide (PHMB), Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Candida albicans

CLC Number:

R978.5

TAN Jing-wen, XU Hong, SONG Jin-feng, GAO Zhi-qin, YANG Hong, YANG Lian-juan, WEN Hai. In vitro antifungal susceptibility of polyhexamethylene biguanide against common superficial fungal species[J]. Chinese Journal of Mycology, 2020, 15(2): 93-96.

References

[1] 闫华, 韩江升, 林煦, 等. 聚六亚甲基双胍盐酸盐的性能、应用与合成进展[J]. 山东化工, 2017, 46(20):47-48.
[2] 李杨, 李付刚. 聚六亚甲基双胍盐酸盐的合成及应用[J]. 精细化工原料及中间体, 2011, (2):27-29.
[3] Yabes JM, White BK, Murray CK, et al.In vitro activity of Manuka Honey and polyhexamethylene biguanide on filamentous fungi and toxicity to human cell lines[J]. Med Mycol, 2017, 55(3):334-343.
[4] Medvedec Miki Ac' I, Cigi Ac' L, Kero D, et al. Antimicrobial effectiveness of polyhexamethylene biguanide on Enterococcus faecalis, Staphylococcus epidermidis and Candida albicans[J]. Med Glas (Zenica), 2018, 15(2):132-138.
[5] National Committee for Clinical Laboratory Standards. Referencemethod for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A2[S]. National Committee for Clinical Laboratory Standards, Wayne, Pa,2008.
[6] National Committee for Clinical Laboratory Standards. Referencemethod for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3[S]. National Committee for Clinical Laboratory Standards, Wayne, Pa,2008.
[7] 陈思敏, 何巧, 谌立巍. 改良琼脂培养基稀释法在抗真菌药物体外敏感性试验中的应用研究[J]. 中药与临床, 2012, 3(6):40-41, 55.
[8] Kovitwanichkanont T, Chong AH. Superficial fungal infections[J]. Aust J Gen Pract, 2019, 48(10):706-711.
[9] 朱均昊, 韩德忞, 赵颖, 等. 上海地区9566例浅部真菌病患者病原菌分析[J]. 中国真菌学杂志, 2016, 11(3):178-180.
[10] 马元龙, 张洲, 吕新翔, 等. 内蒙古医科大学附属医院47年浅部真菌病及病原菌分析[J]. 实用皮肤病学杂志, 2019, 12(3):151-154.
[11] 韦冠京, 梁伶, 曹存巍, 等. 10042例浅部真菌病及其病原菌分析[J]. 中国真菌学杂志, 2017, 12(1):23-28.
[12] 姜伟伟, 扈东营, 侯晴, 等. 1031例皮肤癣菌病及致病菌分析[J]. 中国真菌学杂志, 2019, 14(2):99-103.
[13] 季文英. 浅部真菌病影响患者生活质量的调查分析[J]. 中国真菌学杂志, 2009, 4(3):148-151.
[14] Sibbald RG, Coutts P, Woo KY. Reduction of bacterial burden and pain in chronic wounds using a new polyhexamethylene biguanide antimicrobial foam dressing-clinical trial results[J]. Adv Skin Wound Care, 2011, 24(2):78-84.
[15] 贺元川, 鲁增辉, 陈仕江. 聚六亚甲基双胍对蝙蝠蛾幼虫病原菌粉棒束孢的杀菌效果和毒性评价[J]. 菌物学报, 36(6):766-772.
[16] 戴陈伟, 蔡标, 刁慧敏, 等. 一种聚六亚甲基双胍盐酸盐抗菌液的消毒性能和安全性评价[J]. 中国卫生检验杂志, 2019, 29(5):517-519.
[17] To E, Dyck R, Gerber S, et al. The effectiveness of topical polyhexamethylene biguanide (PHMB) agents for the treatment of chronic wounds:a systematic review[J]. Surg Technol Int, 2016, 29:45-51.
[18] Papa V, Rama P, Radford C, et al. Acanthamoeba keratitis therapy:time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases[J]. Br J Ophthalmol, 2019; 0:1-7.
[19] Dadar M, Tiwari R, Karthik K, et al. Candida albicans-Biology, molecular characterization, pathogenicity, and advances in diagnosis and control-An update[J]. Microb Pathog, 2018, 117:128-138.